NTRK1 and acute lymphoblastic leukemia: For example, two receptor tyrosine kinase inhibitors, Pazopanib, suggested for treating advanced renal cell carcinoma and soft tissue sarcoma, and Ponatinib, suggested for treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, are found to inhibit necroptosis induced by various cell death receptor ligands in human cells, while not protecting from apoptosis.